[go: up one dir, main page]

SV2002000343A - Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb - Google Patents

Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb

Info

Publication number
SV2002000343A
SV2002000343A SV2001000343A SV2001000343A SV2002000343A SV 2002000343 A SV2002000343 A SV 2002000343A SV 2001000343 A SV2001000343 A SV 2001000343A SV 2001000343 A SV2001000343 A SV 2001000343A SV 2002000343 A SV2002000343 A SV 2002000343A
Authority
SV
El Salvador
Prior art keywords
glucogeno
pharmaceutical
fosforilasa
composisions
ref
Prior art date
Application number
SV2001000343A
Other languages
English (en)
Inventor
Dennis Jay Hoover
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000343A publication Critical patent/SV2002000343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y COMO MINIMO UN POLIMERO QUE AUMENTA LA CONCENTRACION. LA COMPOSICION PUEDE SER UNA MEZCLA FISICA SIMPLE DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO QUE AUMENTA LA CONCENTRACION, O UNA DISPERSION DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO.
SV2001000343A 2000-03-16 2001-03-15 Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb SV2002000343A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
SV2002000343A true SV2002000343A (es) 2002-07-03

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000343A SV2002000343A (es) 2000-03-16 2001-03-15 Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb

Country Status (32)

Country Link
US (1) US20010053778A1 (es)
EP (1) EP1263414A1 (es)
JP (1) JP2003526654A (es)
KR (1) KR20020081445A (es)
CN (1) CN1418089A (es)
AP (1) AP2002002621A0 (es)
AR (1) AR027656A1 (es)
AU (1) AU2001242669A1 (es)
BG (1) BG107037A (es)
BR (1) BR0109189A (es)
CA (1) CA2403241A1 (es)
CO (1) CO5280087A1 (es)
CZ (1) CZ20022955A3 (es)
EA (1) EA200200858A1 (es)
EE (1) EE200200530A (es)
HU (1) HUP0204583A2 (es)
IL (1) IL151320A0 (es)
IS (1) IS6508A (es)
MA (1) MA26882A1 (es)
MX (1) MXPA02009097A (es)
NO (1) NO20024386L (es)
OA (1) OA12232A (es)
PA (1) PA8513601A1 (es)
PE (1) PE20011184A1 (es)
PL (1) PL360780A1 (es)
SK (1) SK12622002A3 (es)
SV (1) SV2002000343A (es)
TN (1) TNSN01040A1 (es)
TR (1) TR200202184T2 (es)
WO (1) WO2001068055A1 (es)
YU (1) YU67202A (es)
ZA (1) ZA200207290B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
ATE486586T1 (de) * 2001-06-22 2010-11-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
ES2878403T3 (es) 2002-02-01 2021-11-18 Bend Res Inc Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
RU2288703C2 (ru) 2002-02-01 2006-12-10 Пфайзер Продактс Инк. Способ создания однородных высушенных распылением твердых аморфных лекарственных дисперсных систем с использованием распыляющих напорных форсунок (варианты) и продукт
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2548376A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
WO2005085245A1 (en) 2004-03-08 2005-09-15 Prosidion Limited Pyrrolopyridine-2-carboxylic acid hydrazides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
US20140179749A1 (en) 2012-09-11 2014-06-26 Bend Research Formulations of enzalutamide
CA3128535C (en) 2013-07-19 2024-10-15 Siga Technologies, Inc. PREPARATION OF AMORPHIC TECOVIRIMAT
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP624A (en) * 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
PL360780A1 (en) 2004-09-20
HUP0204583A2 (hu) 2003-04-28
TNSN01040A1 (fr) 2005-11-10
IL151320A0 (en) 2003-04-10
CN1418089A (zh) 2003-05-14
BG107037A (bg) 2003-04-30
AP2002002621A0 (en) 2002-09-30
AU2001242669A1 (en) 2001-09-24
MXPA02009097A (es) 2003-03-12
ZA200207290B (en) 2003-09-11
CA2403241A1 (en) 2001-09-20
NO20024386D0 (no) 2002-09-13
TR200202184T2 (tr) 2003-01-21
MA26882A1 (fr) 2004-12-20
US20010053778A1 (en) 2001-12-20
PE20011184A1 (es) 2001-11-15
EA200200858A1 (ru) 2003-02-27
CZ20022955A3 (cs) 2003-09-17
EE200200530A (et) 2004-04-15
IS6508A (is) 2002-08-16
SK12622002A3 (sk) 2004-02-03
AR027656A1 (es) 2003-04-09
OA12232A (en) 2006-05-10
PA8513601A1 (es) 2004-08-31
WO2001068055A1 (en) 2001-09-20
YU67202A (sh) 2006-01-16
BR0109189A (pt) 2003-05-27
EP1263414A1 (en) 2002-12-11
KR20020081445A (ko) 2002-10-26
JP2003526654A (ja) 2003-09-09
NO20024386L (no) 2002-11-13
CO5280087A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
SV2002000343A (es) Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb
SV2002000581A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester ref.pc10754/700005/bb
SV2004001473A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo ref.pc 23132
BR0207296B1 (pt) composiÇço para revestimento.
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
BR0006005A (pt) Composição estável de óleo em glicerinatopicamente aplicável
BR0101304B1 (pt) "composição de poliolefina que compreende uma mistura de absorvedores de uv e uso de uma mistura de absorvedores de uv".
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BG104916A (en) Calcilytic compounds
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
CY1105009T1 (el) Συνθεση καχαλαλιδης f
NO20011017L (no) Polymeriserings-inhibitering av styren-monomerer
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
BR0000544A (pt) Poliolefinas de metaloceno estabilizadas
DE50205129D1 (de) 8-tetradecenal als duft- oder aromastoff
BR0112727A (pt) Inibidor da polimerização para materiais contendo vinila
BR0210096A (pt) Composição farmacêutica contendo emoliente de fezes tal como poloxâmero e partìculas entéricas revestidas de bissacodil
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
EA200300128A1 (ru) Фармацевтические композиции, содержащие карбонат лития

Legal Events

Date Code Title Description
FD Lapse